The Cancer Letter

Inside information on cancer research and drug development

Letter To The Editor

Gary Schwartz: Monica Bertagnolli is poised to be a visionary NIH director

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As Case Comprehensive Cancer Center’s new director, and on behalf of our membership, I applaud the Biden administration for tapping Monica Bertagnolli, MD, FASCO, as the second female director of the National Institutes of Health (NIH) and congratulate Dr. Bertagnolli on her candidacy. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Gary Schwartz, MD
Director, Case Comprehensive Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Roger Lo awarded $2M NIH grant to study melanoma treatment resistance

Roger Lo, professor of medicine, dermatology, and molecular and medical pharmacology and investigator at the UCLA Health Jonsson Comprehensive Cancer Center, was awarded a $2 million grant from NIH to investigate innovative strategies to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors, a common treatment for patients with melanomas that carry the BRAFV600 mutation.
Byline
Gary Schwartz, MD
Director, Case Comprehensive Cancer Center
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account